XCUR
EXICURE, INC.
$2.92
-1.35%
$18.6M
No data for this timeframe.
Vol
Market Cap$18.6M
Cap SizeNano Cap
Inst. Holders3 funds
Inst. Value$247.4K
Inst. Activity1 buys / 0 sells
SEC Reports2
Press Releases2
Recent Activity
Jun 1, 2026
SEC
Exicure disclosed it received a Nasdaq delinquency notice on May 28, 2026 for late filing of its Q1 2026 10-Q, but filed
8-K — Impact 3/10
Apr 10, 2026
SEC
Exicure, Inc. appointed Yoontae Han as a new director and Chair of the Audit Committee, and Young Seung Ko as Chief Oper
8-K — Impact 3/10
Inst.
MORGAN STANLEY — ADD
3,565 shares ($19.3K)
Inst.
VANGUARD GROUP INC — ADD
42,044 shares ($172.0K)
Jun 1, 2026
Press
Exicure received a Nasdaq non-compliance notice for late filing of its Q1 2026 10-Q, but filed the report on May 29, 202
Impact 4/10
Jun 1, 2026
regulatory
Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q
Exicure announced receipt of a Nasdaq notice related to the delayed filing of its Form 10-Q and conf
Mar 25, 2026
Press
Exicure reported its 2025 financial results, showing a reduced net loss of $4.9 million compared to $9.7 million in 2024
Impact 8/10
Analyst Ratings
0Strong Buy
0Buy
3Hold
1Sell
2Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Aug 16, 2022 | Chardan Capital | MAINTAIN | Neutral |
Latest Reports
NEUTRAL
Press
4/10
Exicure received a Nasdaq non-compliance notice for late filing of its Q1 2026 10-Q, but filed the report on May 29, 202
Jun 1, 2026
NEUTRAL
8-K
3/10
Exicure disclosed it received a Nasdaq delinquency notice on May 28, 2026 for late filing of its Q1 2026 10-Q, but filed
Jun 1, 2026
NEUTRAL
8-K
3/10
Exicure, Inc. appointed Yoontae Han as a new director and Chair of the Audit Committee, and Young Seung Ko as Chief Oper
Apr 10, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $227.9K | ADD |
| MORGAN STANLEY | $19.3K | ADD |
| BANK OF AMERICA CORP | $211.00 | TRIM |
3 institutional holders with $247.4K total value (45,648 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, BANK. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 42,044 | $227.9K | 92.1% | ADD +51.0% |
| 2 | MORGAN STANLEY | 3,565 | $19.3K | 7.8% | ADD +73.5% |
| 3 | BANK OF AMERICA CORP /DE/ | 39 | $211.00 | 0.1% | TRIM -34.3% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 2,055 | 3,565 | +73.5% | $19.3K | 2025-Q4 |
| VANGUARD GROUP INC | ADD | 27,839 | 42,044 | +51.0% | $172.0K | 2025-Q3 |
| UBS Group AG | TRIM | 26,268 | 18,702 | -28.8% | $76.5K | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 612 | 2,055 | +235.8% | $8.4K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 67 | 44 | -34.3% | $180.00 | 2025-Q3 |
| VANGUARD GROUP INC | ADD | 19,033 | 27,839 | +46.3% | $196.0K | 2025-Q2 |
| UBS Group AG | DOUBLED | 566 | 26,268 | +4541.0% | $184.9K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 16 | 67 | +318.8% | $472.00 | 2025-Q2 |
| VANGUARD GROUP INC | NEW | — | 19,033 | — | $253.9K | 2025-Q1 |
| UBS Group AG | TRIM | 1,640 | 566 | -65.5% | $7.5K | 2025-Q1 |
| UBS Group AG | NEAR_EXIT | 9,588 | 1,640 | -82.9% | $22.4K | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
2 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 3.0/10.
Historical analyst distribution (last covering-analyst action Aug 2022): 0% buy across 6 analysts — 0 strong buy, 0 buy, 3 hold, 1 sell, 2 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q 2022-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY 2023-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Aug 16, 2022 | Chardan Capital | MAINTAIN | — | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jan 1, 2023 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Dec 1, 2022 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Nov 1, 2022 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Oct 1, 2022 | 0 | 0 | 3 | 1 | 2 | 0% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 1, 2026
regulatory
Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q
Exicure announced receipt of a Nasdaq notice related to the delayed filing of its Form 10-Q and confirmed that the Form 10-Q was filed on May 29, 2026
Apr 22, 2026
other
Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)
Exicure enters co-development agreement with Adbiotech to advance Burixafor (GPC-100) combination therapies across multiple indications.
Apr 2, 2026
other
Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
Mar 25, 2026
earnings
Exicure, Inc. Reports Full Year 2025 Financial Results
Exicure, Inc. Reports Full Year 2025 Financial Results
Mar 25, 2026
earnings
Exicure, Inc. Reports Full Year 2025 Financial Results
Exicure, Inc. Reports Full Year 2025 Financial Results
Mar 16, 2026
earnings_calendar
XCUR Q4 2025 Earnings After Market Close — 2026-03-16